This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

The desire of digital health companies to scale through mergers and acquisitions or partnerships was one of the most ...

Healthcare leaders shared insights on various topics, including industry challenges, a new administration and growing their ...

What does Trump's decision to leave the WHO mean for public health? And should U.S. companies be intimidated by Chinese drug ...

Their ongoing efforts and future initiatives reflect a strong commitment to advancing healthcare solutions for patients in need. Please note that all information presented here is based on the ...

Overall, Jazz Pharmaceuticals showcased a robust financial update and a strategic outlook aimed at driving innovation, transformative therapies, and long-term value creation in the healthcare sector.

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

The health system brought in $18 billion in annualized revenue in 2024, executives said during their presentation at the J.P. Morgan Healthcare Conference in San Francisco last week. The health ...

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...